Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

STAR Medical has exclusive rights to the STAR® biomaterial from the University of Washington in Seattle (USA) for ophthalmic use. The porous material exhibits outstanding anti-fibrotic and anti-inflammatory properties providing the foundation for the development of MINIjectTM, designed to be a best-in-class micro-invasive glaucoma surgery (MIGS) device. MIGS is the most promising and fastest-growing therapeutic option for the...
STAR Medical has exclusive rights to the STAR® biomaterial from the University of Washington in Seattle (USA) for ophthalmic use. The porous material exhibits outstanding anti-fibrotic and anti-inflammatory properties providing the foundation for the development of MINIjectTM, designed to be a best-in-class micro-invasive glaucoma surgery (MIGS) device. MIGS is the most promising and fastest-growing therapeutic option for the treatment of glaucoma. The fast-growing glaucoma surgical device market is expected to reach $1.84 bn worldwide by 2025.The company is backed by specialised institutional and private investors.

List your booth number for exhibitions, ask us